Avagacestat, an oral gamma-secretase inhibitor, did not demonstrate efficacy in the treatment of patients with so-called prodromal Alzheimer's disease (PDAD) and was associated with adverse dose-limiting effects in a randomized, placebo-controlled trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.